Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the fields of Immuno-Oncology and Inflammatory Diseases. The company’s discovery and development programs are centered around its two patented transgenic mouse platforms generating fully human monoclonal antibodies.
The company is building its proprietary pipeline through internal discovery research, collaboration with co-development partners, and acquisition of innovative preclinical and clinical stage assets. In addition, Harbour BioMed also out-licenses the H2L2 and HCAb mouse platforms to companies and academic institutions through its subsidiary Harbour Antibodies.
Harbour BioMed is a global biopharmaceutical company with R&D facilities, clinical development, and business development teams located in Shanghai; research innovation and business development operations located in Boston, USA; and an antibody platform innovation center located in Rotterdam, The Netherlands.